clinical trial · NCT03840148
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
Venatorx Pharmaceuticals, Inc.·phase3·completed·n = 661
Urinary Tract InfectionsAcute PyelonephritisCefepime/VNRX-5133 (taniborbactam)Meropenem
brief summary
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
started
Aug 7, 2019
primary completion
Dec 14, 2021
completion
Dec 14, 2021
last updated
Jun 6, 2025
official title
A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol